PRESS RELEASE published on 08/14/2024 at 14:00, 2 years 1 month ago Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Xenetic Biosciences, Inc. reports financial results for Q2 2024, focusing on DNase-based oncology program in preclinical studies with data due before year end. Ended quarter with $7.3M cash Financial Results Xenetic Biosciences Cash Balance DNase-based Oncology Program Preclinical Studies
BRIEF published on 05/22/2024 at 23:05, 2 years 4 months ago Xenetic Biosciences, Inc. annonce une transition de direction Développement Clinique Oncologie Leadership Executif Biosciences Xénétiques James Parslow
BRIEF published on 05/22/2024 at 23:05, 2 years 4 months ago Xenetic Biosciences, Inc. Announces Executive Leadership Transition Xenetic Biosciences Oncology Clinical Development Executive Leadership James Parslow
PRESS RELEASE published on 05/22/2024 at 23:00, 2 years 4 months ago Xenetic Biosciences, Inc. Announces Executive Leadership Transition Xenetic Biosciences appoints James F. Parslow as interim CEO. The company focuses on innovative immune-oncology technologies for hard-to-treat cancers Xenetic Biosciences Clinical Development Pancreatic Carcinoma James Parslow Immune-oncology Technologies
BRIEF published on 05/10/2024 at 14:35, 2 years 4 months ago Xenetic Biosciences publie ses résultats financiers et ses progrès commerciaux pour le premier trimestre 2024 Résultats Financiers Biosciences Xénétiques Programme D'oncologie Thérapie Basée Sur La DNase Etudes Précliniques
BRIEF published on 05/10/2024 at 14:35, 2 years 4 months ago Xenetic Biosciences Reports Q1 2024 Financial Results and Business Progress Financial Results Xenetic Biosciences Oncology Program DNase-based Therapy Preclinical Studies
PRESS RELEASE published on 05/10/2024 at 14:30, 2 years 4 months ago Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Xenetic Biosciences, Inc. reports financial results for Q1 2024 and progress on DNase-based oncology program, including ongoing preclinical studies and funds of $7.8 million Financial Results Xenetic Biosciences DNase-based Oncology Program Preclinical Studies Cash Reserves
BRIEF published on 03/22/2024 at 13:05, 2 years 6 months ago Xenetic Biosciences, Inc. présente ses performances financières et ses progrès en matière de développement pour l'année 2023 Résultats Financiers Produits Biopharmaceutiques Biosciences Xénétiques Programme D'oncologie Plateforme DNase
BRIEF published on 03/22/2024 at 13:05, 2 years 6 months ago Xenetic Biosciences, Inc. Presents Full Year 2023 Financial Performance and Development Progress Financial Results Xenetic Biosciences Biopharmaceuticals Oncology Program DNase Platform
PRESS RELEASE published on 03/22/2024 at 13:00, 2 years 6 months ago Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results Xenetic Biosciences reports financial results for 2023, highlighting progress on DNase-based oncology program leading to Phase 1 study for pancreatic carcinoma & solid tumors, ending year with $9.0 million Financial Results Xenetic Biosciences Solid Tumors DNase-based Oncology Program Pancreatic Carcinoma
Published on 09/24/2026 at 11:00, 1 hour 7 minutes ago Silver Range Defines Targets at the Drum Property in Utah
Published on 09/24/2026 at 08:00, 4 hours 7 minutes ago Caledonia Mining Corporation Plc: Notification of Relevant Change to Significant Shareholder
Published on 09/23/2026 at 22:00, 14 hours 7 minutes ago Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 17 hours 42 minutes ago Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 20 hours 25 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/24/2026 at 11:05, 1 hour 1 minute ago GEOSAT BECOMES FIRST EUROPEAN PARTNER IN THE SDG DATA ALLIANCE
Published on 09/24/2026 at 11:02, 1 hour 4 minutes ago Custodian Property Income REIT plc: Share Buyback
Published on 09/24/2026 at 11:00, 1 hour 7 minutes ago hep global successfully develops its largest solar project to date in Germany, with a capacity of 35.7 MWp
Published on 09/24/2026 at 11:00, 1 hour 7 minutes ago ABB Ltd: ABB share buybacks - September 17, 2026 - September 23, 2026
Published on 09/24/2026 at 08:00, 4 hours 7 minutes ago Neoen launches construction of 3 solar farms and a wind farm in France, with a total capacity of 101 MW
Published on 09/24/2026 at 08:00, 4 hours 7 minutes ago Neoen lance la construction de trois parcs solaires et un parc éolien en France pour une capacité totale de 101 MW
Published on 09/24/2026 at 07:30, 4 hours 37 minutes ago Gimv rondt met succes private plaatsing van een obligatie af voor een bedrag van EUR 150 miljoen
Published on 09/24/2026 at 07:30, 4 hours 37 minutes ago Gimv successfully completes private placement of a bond for an amount of EUR 150 million
Published on 09/24/2026 at 07:30, 4 hours 37 minutes ago Gimv successfully completes private placement of a bond for an amount of EUR 150 million
